Market Research Logo

Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Scope

The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.

Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.
  • Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
  • What CAGR will these companies register in the forecast period?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
  • Visualize the composition of the dermatology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various dermatological conditions.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.


Global Dermatology Market Set to Reach $33.7 Billion by 2022, Despite Patent Expiries, says GBI Research

The global dermatology market is set to experience strong growth from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%, says business intelligence provider GBI Research.

According to the company’s latest report*, such an impressive rise will occur in spite of the patent expiries of many marketed monoclonal Antibodies (mAbs), which are unlikely to have a significant impact due to the practical and regulatory barriers faced by biosimilars. Growth will be driven by a strong late-stage pipeline, which includes several highly valuable targeted therapies, such as dupilumab, AN-2729, AMG-827 and ixekizumab.

Jennifer Goossens, Associate Analyst for GBI Research, states that: “There exists a significant unmet need for improved treatment options across dermatology indications, as physicians often cite poor efficacy, low patient compliance, and problematic safety profiles with the long-term use of many available treatments. This is especially true for patients with severe disease who rely on general immunosuppressive drugs.

“There are currently a number of promising biologics in the pipeline for major skin disorders, including atopic dermatitis, acne vulgaris and rosacea, with 17 biologics in Phase III of development. This sizeable number suggests that they could have a considerable impact on treatment algorithms in the dermatology therapy area over the forecast period.”

In terms of specific products, Regeneron/Sanofi’s dupilumab is the leading candidate to bring about a paradigm shift in the treatment moderate-to-severe atopic dermatitis. At the same time, the use of older systemic immunosuppressants in dermatology is likely to decrease once biologics for other key indications besides psoriasis enter the market from 2016.

However, GBI Research believes the dermatology space is not likely to experience major shifts in terms of its big players by 2022.

Goossens concludes: “Key market players, namely Johnson & Johnson, AbbVie, Amgen, Novartis, and Roche, are expected to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries – especially AbbVie’s Humira and Johnson & Johnson’s Remicade – will affect these companies directly.”

*Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

This report provides analysis of the global dermatology treatment space, focusing specifically on atopic dermatitis, acne vulgaris, and psoriasis. It includes annualized market data from 2015 and forecast to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Atopic Dermatitis
2.3.2 Acne Vulgaris
2.3.3 Psoriasis
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.5.1 Atopic Dermatitis
2.5.2 Acne Vulgaris
2.5.3 Psoriasis
2.6 Treatment
2.6.1 Topical Corticosteroids
2.6.2 Calcineurin Inhibitors
2.6.3 Retinoids
2.6.4 Systemic Immunosuppressive Agents
2.6.5 Biologics
2.6.6 Antihistamines
2.6.7 Hormonal Therapy
2.6.8 Moisturizers
3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab)
3.3 Remicade (infliximab)
3.4 Enbrel (etanercept)
3.5 Stelara (ustekinumab)
3.6 Neoral (cyclosporine)
3.7 Protopic (tacrolimus)
3.8 Elidel (pimecrolimus)
3.9 Elocon (mometasone furoate)
3.10 Differin (adapalene)
3.11 Metolate (methotrexate)
3.12 Clobex (clobetasol propionate)
3.13 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Molecule Types in the Pipeline
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Conclusion
5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Tumor Necrosis Factor-Alpha
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
5.3.3 Calcineurin
5.3.4 Glucocorticoid Receptors
5.3.5 Phosphodiesterase 4
5.3.6 Revenue and Market Share Analysis by Company
5.3.7 Assessment of Key Pipeline Products
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 References
8.2 Table of Epidemiology Forecast
8.3 Table of All Clinical Stage Pipeline Products
8.4 Abbreviations
8.5 Disease List
8.6 Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Market Size and Revenue Forecasts
8.6.4 Pipeline Analysis
8.6.5 Competitive Landscape
8.7 Contact Us
8.8 Disclaimer
1.1 List of Tables
Table 1: Dermatology, Global, Epidemiology of Dermatological Disorders, 2015
Table 2: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2015
Table 3: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2015
Table 4: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2015
Table 5: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2015
Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2015
Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2015
Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015
Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015
Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015
Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2015
Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2015
Table 13: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
Table 14: Dermatology, Global, Usage of Generics Across Key Indications, 2015
Table 15: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022
Table 16: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2016
Table 17: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2016
Table 18: Epidemiology Patterns for Atopic Dermatitis, 2015-2022
Table 19: Epidemiology Patterns for Acne Vulgaris, 2015-2022
Table 20: Epidemiology Patterns for Psoriasis, 2015-2022
Table 21: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016
Table 22: Abbreviations
1.2 List of Figures
Figure 1: Epidemiology Patterns for Atopic Dermatitis (Million), 2015-2022
Figure 2: Epidemiology Patterns for Acne Vulgaris (Million), 2015-2022
Figure 3: Epidemiology Patterns for Psoriasis (Million), 2015-2022
Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2015
Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2022
Figure 6: Dermatology Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006-2022
Figure 7: Dermatology Therapeutics Market, Global, Annual Revenue for Enbrel ($bn), 2006-2022
Figure 8: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2022
Figure 9: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2022
Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2022
Figure 11: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 12: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2016
Figure 13: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2016
Figure 14: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2016
Figure 15: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2016
Figure 16: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2016
Figure 17: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 18: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 19: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 20: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 21: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 22: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 23: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 24: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 25: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 29: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
Figure 30: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 31: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 32: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 33: Dermatology Global, Market Size ($bn), 2015-2022
Figure 34: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
Figure 35: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015-2022
Figure 36: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
Figure 37: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022
Figure 38: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022
Figure 39: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2022
Figure 40: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 41: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 42: Dermatology, Global, Revenues by Product Type, 2015-2022
Figure 43: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
Figure 44: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2015-2022
Figure 45: Dermatology, Global, Amgen Annual Revenue Forecast ($bn), 2015-2022
Figure 46: Dermatology, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022
Figure 47: Dermatology, Global, Roche Annual Revenue Forecast ($bn), 2015-2022
Figure 48: Dermatology, Global, Merck Annual Revenue Forecast ($bn), 2015-2022
Figure 49: Dermatology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015-2022
Figure 50: Dermatology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2016-2022
Figure 51: Dermatology Therapeutics Market, Global, Revenue Forecast for dupilumab ($m), 2016-2022
Figure 52: Dermatology Therapeutics Market, Global, Revenue Forecast for AN-2728 ($m), 2016-2022
Figure 53: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022
Figure 54: Dermatology Therapeutics Market, Global, Revenue Forecast for guselkumab ($m), 2016-2022
Figure 55: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 56: Dermatology, Global, Companies by Type, 2016
Figure 57: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2016
Figure 58: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022
Figure 59: Dermatology, Global, Licensing Deals, 2006-2016
Figure 60: Dermatology, Global, Licensing Deals by Indication, 2006-2016
Figure 61: Dermatology, Global, Licensing Deals, 2006-2016
Figure 62: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
Figure 63: Dermatology, Global, Co-development Deals, 2006-2016
Figure 64: Dermatology, Global, Co-development Deals by Indication, 2006-2016
Figure 65: Dermatology, Global, Co-development Deals, 2006-2016
Figure 66: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report